Adma Biologics (ADMA) Other Non-Current Liabilities (2012 - 2025)
Adma Biologics (ADMA) reported Other Non-Current Liabilities of $90000.0 for Q3 2025, down 76.0% on a YoY basis from $375000.0 in Q3 2024, and up 4400.0% quarter-over-quarter from $2000.0 in Q2 2025.
Adma Biologics (ADMA) Other Non-Current Liabilities (2012 - 2025) Analysis & Trends
Adma Biologics has reported Other Non-Current Liabilities for 13 years, with the latest figure at $90000.0 in Q3 2025.
- For the quarter ending Q3 2025, Other Non-Current Liabilities fell 76.0% year-over-year to $90000.0; the trailing twelve-month figure through Sep 2025 stood at $90000.0 (down 76.0% YoY), and the FY2024 full-year result was $360000.0, down 14.08% from the prior year.
- Other Non-Current Liabilities for Q3 2025 stood at $90000.0, up from $2000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $768538.0 in Q1 2021, with the low at $2000.0 in Q1 2025.
- Historically, Other Non-Current Liabilities has averaged $324858.2 across 5 years, with a median of $373903.0 in 2022.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities jumped 934.28% — and 2025, when it slumped 99.51%.
- Adma Biologics' Other Non-Current Liabilities stood at $397351.0 in 2021, then dropped by 11.92% to $350000.0 in 2022, then climbed by 19.71% to $419000.0 in 2023, then slipped by 14.08% to $360000.0 in 2024, then slumped by 75.0% to $90000.0 in 2025.
- The last three Other Non-Current Liabilities figures came in at $90000.0 (Q3 2025), $2000.0 (Q2 2025), and $2000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Adma Biologics | 1.98 Bn | 1.89 Bn | 88.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 90,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Mar 31, 2025 | 2,000.00 |
| Dec 31, 2024 | 360,000.00 |
| Sep 30, 2024 | 375,000.00 |
| Jun 30, 2024 | 390,000.00 |
| Mar 31, 2024 | 405,000.00 |
| Dec 31, 2023 | 419,000.00 |
| Sep 30, 2023 | 434,647.00 |
| Jun 30, 2023 | 449,513.00 |
| Mar 31, 2023 | 338,731.00 |
| Dec 31, 2022 | 350,000.00 |
| Sep 30, 2022 | 362,179.00 |
| Jun 30, 2022 | 373,903.00 |
| Mar 31, 2022 | 385,628.00 |
| Dec 31, 2021 | 397,351.00 |
| Sep 30, 2021 | 232,665.00 |
| Jun 30, 2021 | 36,151.00 |
| Mar 31, 2021 | 768,538.00 |
| Dec 31, 2020 | 54,886.00 |